US5026687A
(en)
|
1990-01-03 |
1991-06-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
|
AU4671193A
(en)
|
1992-07-13 |
1994-01-31 |
Kenneth E. Sherman |
Composition and method of treating hepatitis b
|
US6107027A
(en)
|
1994-12-14 |
2000-08-22 |
University Of Washington |
Ribozymes for treating hepatitis C
|
GB9505025D0
(en)
|
1995-03-13 |
1995-05-03 |
Medical Res Council |
Chemical compounds
|
US6387365B1
(en)
|
1995-05-19 |
2002-05-14 |
Schering Corporation |
Combination therapy for chronic hepatitis C infection
|
US5980884A
(en)
|
1996-02-05 |
1999-11-09 |
Amgen, Inc. |
Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
|
GB9605293D0
(en)
|
1996-03-13 |
1996-05-15 |
Glaxo Group Ltd |
Medicaments
|
US5922757A
(en)
|
1996-09-30 |
1999-07-13 |
The Regents Of The University Of California |
Treatment and prevention of hepatic disorders
|
AU5157998A
(en)
|
1996-11-01 |
1998-05-29 |
Thomas Najarian |
Methods and compositions for treatment of hepatitis c infection
|
IL119833A
(en)
|
1996-12-15 |
2001-01-11 |
Lavie David |
Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
|
US6103706A
(en)
|
1997-04-29 |
2000-08-15 |
New York Blood Center, Inc. |
Methods for treating viral infections
|
US6010890A
(en)
|
1997-04-29 |
2000-01-04 |
New York Blood Center, Inc. |
Method for viral inactivation and compositions for use in same
|
US6143752A
(en)
|
1997-08-01 |
2000-11-07 |
Oren; Ran |
Method for preventing or arresting liver damage in humans
|
EP1136075B1
(en)
|
1997-09-21 |
2003-01-15 |
Schering Corporation |
Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
|
JP3838034B2
(ja)
|
1997-10-13 |
2006-10-25 |
大塚製薬株式会社 |
C型肝炎治療効果の改善剤及びその応用
|
FR2771637B1
(fr)
|
1997-12-01 |
2003-10-24 |
Hutchinson |
Utilisation d'un halogenure de dialkyldialkylammonium par voie parenterale dans les infections bacteriennes et virales
|
EP1037636A4
(en)
|
1997-12-11 |
2004-08-18 |
Univ Oxford |
INHIBITATION OF MEMBRANE-TIED VIRAL REPLICATION
|
WO1999030721A1
(en)
|
1997-12-17 |
1999-06-24 |
Cornell Research Foundation, Inc. |
Cyclooxygenase-2 inhibition
|
US7462605B2
(en)
|
1998-01-23 |
2008-12-09 |
Celmed Oncology (Usa), Inc. |
Phosphoramidate compounds and methods of use
|
WO1999049873A1
(en)
|
1998-03-27 |
1999-10-07 |
Regents Of The University Of Minnesota |
Nucleosides with antiviral and anticancer activity
|
JP2000007578A
(ja)
|
1998-06-24 |
2000-01-11 |
Hiroaki Okushin |
C型肝炎ウイルスの陰性化のための投薬システム
|
CN1218958C
(zh)
|
1998-07-01 |
2005-09-14 |
德比奥药物股份有限公司 |
活性范围改善的环孢菌素
|
RU2158604C2
(ru)
|
1998-07-03 |
2000-11-10 |
Толоконская Наталья Петровна |
Способ лечения вирусного гепатита c
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
JP2002527522A
(ja)
|
1998-10-16 |
2002-08-27 |
シェリング・コーポレーション |
慢性C型肝炎感染を有する患者における検出可能HCV−RNA根絶用リバビリン−インターフェロン−α併用療法
|
US6403564B1
(en)
|
1998-10-16 |
2002-06-11 |
Schering Corporation |
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
|
US20080275005A1
(en)
|
1998-11-25 |
2008-11-06 |
Murphy Michael P |
Mitochondrially targeted antioxidants
|
AR021876A1
(es)
|
1998-12-18 |
2002-08-07 |
Schering Corp |
Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
|
US6824768B2
(en)
|
1998-12-18 |
2004-11-30 |
Schering Corporation |
Ribavirin-pegylated interferon alfa induction HCV combination therapy
|
AU2156900A
(en)
|
1998-12-18 |
2000-07-12 |
Schering Corporation |
Ribavirin-interferon alfa induction hcv combination therapy
|
JP2000212099A
(ja)
|
1999-01-19 |
2000-08-02 |
Mochida Pharmaceut Co Ltd |
ウイルス性肝炎治療剤
|
ATE286407T1
(de)
|
1999-02-13 |
2005-01-15 |
Purepulse Technologies Inc |
Verfahren zur inaktivierung von pathogenen mittels breitspektrum-pulslicht
|
GB2355932B
(en)
|
1999-04-12 |
2004-01-07 |
Univ Madras |
A pharmaceutical formulation suitable for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation
|
US6849254B1
(en)
|
1999-04-19 |
2005-02-01 |
Schering Corporation |
HCV combination therapy
|
WO2002038105A2
(en)
|
2000-11-08 |
2002-05-16 |
Slil Biomedical Corporation |
Novel polyamine analog-amino acid conjugates useful as anticancer agents
|
ATE429438T1
(de)
|
1999-07-22 |
2009-05-15 |
Celmed Oncology Usa Inc |
Enzym katalisierte therapeutische aktivierung
|
MXPA02001296A
(es)
|
1999-08-13 |
2002-07-22 |
Hoffmann La Roche |
Micofenolato mofetil en asociacion con peg-ifn-alfa.
|
US20050245502A1
(en)
|
1999-08-23 |
2005-11-03 |
Phoenix Biosciences |
Treatments for viral infections
|
KR100392292B1
(ko)
|
2000-01-07 |
2003-07-22 |
주식회사 펩트론 |
5원환 융합 방향족 헤테로사이클릭 화합물을 유효성분으로 하는 hcv 치료제 조성물
|
WO2001077091A2
(en)
|
2000-04-05 |
2001-10-18 |
Tularik Inc. |
Ns5b hcv polymerase inhibitors
|
US7018796B2
(en)
|
2000-04-07 |
2006-03-28 |
Shionogi & Co., Ltd. |
Preincubation assay methods
|
CA2406140A1
(en)
|
2000-04-18 |
2001-10-25 |
Virco Bvba |
Methods for measuring drug resistance
|
US6415797B1
(en)
|
2000-07-07 |
2002-07-09 |
First Circle Medical, Inc. |
Treatment of human herpesviruses using hyperthermia
|
PL206255B1
(pl)
|
2000-07-21 |
2010-07-30 |
Dendreon Corporationdendreon Corporation |
Inhibitor proteazy wirusa zapalenia wątroby C, zawierająca go kompozycja farmaceutyczna i zastosowanie inhibitora do wytwarzania leku do leczenia chorób związanych z HCV oraz zastosowanie do wytwarzania kompozycji do stosowania w kombinowanej terapii
|
US7244721B2
(en)
|
2000-07-21 |
2007-07-17 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
MXPA03001039A
(es)
|
2000-08-02 |
2004-09-10 |
Johnson & Johnson |
Quimioterapia anti-viral y anti-tumor mejorada mediante administracion de eritropoeitina.
|
SV2003000617A
(es)
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
DE50110956D1
(de)
|
2000-10-12 |
2006-10-19 |
Viromics Gmbh |
Proteasome inhibitoren zur behandlung von hepatitis-virus infektionen
|
AU1632302A
(en)
|
2000-10-13 |
2002-04-22 |
Richard Boyd |
Disease prevention by reactivation of the thymus
|
US20020127203A1
(en)
|
2000-10-18 |
2002-09-12 |
Albrecht Janice K. |
Ribavirin-pegylated interferon alfa HCV combination therapy
|
FR2815543B1
(fr)
|
2000-10-19 |
2003-10-24 |
Sedat |
Seringue d'auto-injection d'un melange extemporane
|
DE60135481D1
(de)
|
2000-10-20 |
2008-10-02 |
Genetics Inst |
Verwendung von il-13 inhibitoren zur behandlung von tumoren
|
AU2002245081A1
(en)
|
2000-12-06 |
2002-07-16 |
The Trustees Of The University Of Pennsylvania |
Single therapy and combination therapy involving drugs with target cellular proteins and drugs which target pathogen-encoded proteins
|
AU2002243791B2
(en)
|
2001-01-22 |
2006-06-29 |
Isis Pharmaceuticals, Inc. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
US7105499B2
(en)
|
2001-01-22 |
2006-09-12 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
CN1245215C
(zh)
|
2001-02-28 |
2006-03-15 |
四川省生物工程研究中心 |
重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
|
GB0107924D0
(en)
|
2001-03-29 |
2001-05-23 |
Angeletti P Ist Richerche Bio |
Inhibitor of hepatitis C virus NS3 protease
|
US6673775B2
(en)
|
2001-04-18 |
2004-01-06 |
Schering Corporation |
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
|
AU2002259130A1
(en)
|
2001-05-03 |
2002-11-18 |
Eli Lilly And Company |
Agents for treatment of hcv and methods of use
|
US6833351B2
(en)
|
2001-05-21 |
2004-12-21 |
Douglas T. Dieterich |
Method of treating anemia caused by ribavirin treatment of hepatitis C using erythropoietin alpha
|
JP2004522803A
(ja)
|
2001-06-29 |
2004-07-29 |
マキシゲン・エイピーエス |
インターフェロン製剤
|
US20030138403A1
(en)
|
2001-06-29 |
2003-07-24 |
Maxygen Aps |
Interferon formulations
|
MXPA04000630A
(es)
|
2001-07-20 |
2005-02-17 |
Intermune Inc |
Metodo para tratar fibrosis del higado.
|
WO2003024461A1
(en)
|
2001-09-20 |
2003-03-27 |
Schering Corporation |
Hcv combination therapy
|
BR0212928A
(pt)
|
2001-09-28 |
2004-10-13 |
Intermune Inc |
Processo para tratamento de infecção viral de hapatite c em pacientes que não responderam a tratamento
|
PL369129A1
(en)
|
2001-09-28 |
2005-04-18 |
Intermune, Inc. |
Method for treating hepatitis c virus infection in treatment failure patients
|
BR0213103A
(pt)
|
2001-10-05 |
2004-09-21 |
Intermune Inc |
Método para tratamento de infecção pelo vìrus da hepatite com um perfil de liberação de interferon multifásico
|
PE20030545A1
(es)
|
2001-10-31 |
2003-06-19 |
Schering Corp |
Formulaciones de jarabe de ribavirina
|
WO2003037908A1
(en)
|
2001-10-31 |
2003-05-08 |
Ribapharm Inc. |
Antiviral combination therapy and compositions
|
EP1444330A1
(en)
|
2001-11-07 |
2004-08-11 |
Kirin Beer Kabushiki Kaisha |
Expansion of t cells in vitro and expanded t cell populations
|
AUPR879601A0
(en)
|
2001-11-09 |
2001-12-06 |
Biota Scientific Management Pty Ltd |
Novel chemical compounds and their use
|
US20050095224A1
(en)
|
2001-12-07 |
2005-05-05 |
Ramachandran Radhakrishnan |
Compositions and method for treating hepatitis virus infection
|
DE60221627D1
(de)
|
2001-12-21 |
2007-09-20 |
Virochem Pharma Inc |
Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
|
US6906190B2
(en)
|
2002-01-04 |
2005-06-14 |
Ribapharm Inc. |
Inhibitors for de novo-RNA polymerases and methods of identifying targets for same
|
RU2212248C1
(ru)
|
2002-01-21 |
2003-09-20 |
Государственное образовательное учреждение высшего профессионального образования Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова |
Способ лечения больных хроническим вирусным гепатитом c
|
WO2003072135A2
(en)
|
2002-02-26 |
2003-09-04 |
North Shore-Long Island Jewish Research Insitute |
Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
|
CA2383243A1
(en)
|
2002-04-23 |
2003-10-23 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Method for inhibiting fibrogenesis
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
US20040034206A1
(en)
|
2002-05-31 |
2004-02-19 |
Schering Corporation |
Combination therapy for RNA virus infections involving ribavirin and IMPDH inhibitors
|
TWI334785B
(en)
|
2002-06-03 |
2010-12-21 |
Serono Lab |
Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
|
US7608600B2
(en)
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
PT2206517T
(pt)
|
2002-07-03 |
2023-11-07 |
Tasuku Honjo |
Composições de imunopotenciação contendo anticorpos anti-pd-l1
|
ITMI20021860A1
(it)
|
2002-08-28 |
2004-02-29 |
Scalia Antonio Cassar |
Impiego dei triptani come agenti antivirali.
|
US20060223145A1
(en)
|
2002-11-01 |
2006-10-05 |
Lohray Braj B |
Method for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris
|
WO2004043435A2
(en)
|
2002-11-13 |
2004-05-27 |
Control Delivery Systems, Inc. |
Systemic delivery of antiviral agents
|
WO2004047673A2
(en)
|
2002-11-21 |
2004-06-10 |
Novacea, Inc. |
Treatment of liver disease with active vitamin d compounds
|
BRPI0407587A
(pt)
|
2003-02-18 |
2006-02-14 |
Pfizer |
inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam
|
EP1601368A2
(en)
|
2003-02-28 |
2005-12-07 |
Intermune, Inc. |
Methods and compositions for treatment of viral diseases
|
WO2004078127A2
(en)
|
2003-02-28 |
2004-09-16 |
Intermune, Inc. |
Continuous delivery methods for treating hepatitis virus infection
|
AU2003225670A1
(en)
|
2003-02-28 |
2004-09-28 |
Intermune, Inc. |
Interferon drug therapy for the treatment of viral diseases and liver fibrosis
|
TWI269656B
(en)
|
2003-03-05 |
2007-01-01 |
Original Image Co Ltd |
Therapeutical composition for hepatitis C
|
UA64191A
(en)
|
2003-03-14 |
2004-02-16 |
Yevhenii Mykhailovych Neiko |
Method for treating chronic hepatitises of various etiology
|
US20040198840A1
(en)
|
2003-04-02 |
2004-10-07 |
Deloach Reuben Edwin |
Hydrazide substrate safely shuts down disease activated protease to halt viral replication, cancerous cell division, and toxic protein generation
|
EP2033654B1
(en)
|
2003-04-16 |
2012-05-16 |
Bristol-Myers Squibb Company |
Process for resolving a mixture of alkyl ester enantiomers using an enzyme
|
US20040258663A1
(en)
|
2003-05-08 |
2004-12-23 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of interferon alpha
|
WO2005000308A2
(en)
|
2003-05-15 |
2005-01-06 |
Rigel Pharmaceuticals, Inc. |
Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
|
EA009295B1
(ru)
|
2003-05-21 |
2007-12-28 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Соединения в качестве ингибиторов вируса гепатита с
|
EP2345658A1
(en)
|
2003-05-30 |
2011-07-20 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
US20050187170A1
(en)
|
2003-06-16 |
2005-08-25 |
Biocryst Pharmaceuticals, Inc. |
Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
|
KR20060052709A
(ko)
|
2003-06-20 |
2006-05-19 |
바이럴 게노믹스, 인크. |
항바이러스 조성물 및 그의 사용 방법
|
US20070087982A1
(en)
|
2003-07-11 |
2007-04-19 |
Nelson Jay A |
Methods of treatment and diagnosis using modulators of virus-induced cellular gene sequences
|
MD2549G2
(ro)
|
2003-07-18 |
2005-08-31 |
Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова |
Metodă de tratament a hepatitei virale cronice C.
|
GB0317009D0
(en)
|
2003-07-21 |
2003-08-27 |
Univ Cardiff |
Chemical compounds
|
WO2005018330A1
(en)
|
2003-08-18 |
2005-03-03 |
Pharmasset, Inc. |
Dosing regimen for flaviviridae therapy
|
ATE465742T1
(de)
|
2003-09-05 |
2010-05-15 |
Anadys Pharmaceuticals Inc |
Tlr7-liganden zur behandlung von hepatitis c
|
WO2005023289A1
(ja)
|
2003-09-08 |
2005-03-17 |
Intellectual Property Consulting Incorporated |
慢性c型肝炎を治療するための医薬組成物
|
AR045870A1
(es)
|
2003-10-11 |
2005-11-16 |
Vertex Pharma |
Terapia de combinacion para la infeccion de virus de hepatitis c
|
AU2004281780B2
(en)
|
2003-10-14 |
2009-03-19 |
F. Hoffmann-La Roche Ltd |
Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
|
US7491794B2
(en)
|
2003-10-14 |
2009-02-17 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
WO2005038056A1
(en)
|
2003-10-14 |
2005-04-28 |
Intermune, Inc. |
Combination therapy for the treatment of viral diseases
|
US20050085528A1
(en)
|
2003-10-17 |
2005-04-21 |
Pfizer Inc. |
Parmaceutical
|
CN1898569A
(zh)
|
2003-10-24 |
2007-01-17 |
伊缪因艾德有限公司 |
治疗方法
|
CN1893978A
(zh)
|
2003-10-27 |
2007-01-10 |
沃泰克斯药物股份有限公司 |
用于hcv治疗的组合
|
US8187874B2
(en)
|
2003-10-27 |
2012-05-29 |
Vertex Pharmaceuticals Incorporated |
Drug discovery method
|
UA68233A
(en)
|
2003-11-25 |
2004-07-15 |
Univ Zaporizhia State Medical |
Method for treating chronic hepatitis c
|
US7078064B2
(en)
|
2003-12-03 |
2006-07-18 |
George Zabrecky |
Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
|
ATE544765T1
(de)
|
2003-12-22 |
2012-02-15 |
Leuven K U Res & Dev |
Imidazoä4,5-cüpyridinverbindungen und verfahren zur antiviralen behandlung
|
WO2005062949A2
(en)
|
2003-12-23 |
2005-07-14 |
Intermune, Inc. |
Method for treating hepatitis virus infection
|
US20070258946A1
(en)
|
2003-12-23 |
2007-11-08 |
Blatt Lawrence M |
Combination Therapy for Treating Hepatitis C Virus Infection
|
WO2005067963A1
(en)
|
2003-12-23 |
2005-07-28 |
Intermune, Inc. |
Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
|
DE10361944A1
(de)
|
2003-12-31 |
2005-07-28 |
Viromics Gmbh |
Mittel zur Hemmung der Virusreplikation durch Regulation der Proteinfaltung
|
US20080234182A1
(en)
|
2007-03-22 |
2008-09-25 |
Innovative Biologics, Inc. |
Blockers of pore-forming virulence factors and their use as anti-infectives
|
EP1718315A4
(en)
|
2004-02-06 |
2008-08-13 |
Univ Monash |
HIGH-DOSE USE AND SHORT INTERVAL OF SULFATE POLYSACCHARIDES IN THE TREATMENT OF INFECTIONS
|
US7205330B2
(en)
|
2004-02-27 |
2007-04-17 |
Schering Corporation |
Inhibitors of hepatitis C virus NS3 protease
|
WO2005102353A1
(en)
|
2004-04-22 |
2005-11-03 |
Howard J Smith & Associates Pty Ltd |
Supportive treatment of liver disease
|
CA2564503C
(en)
|
2004-05-04 |
2015-12-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibition of mir-122 in hepatitis c virus infected subjects and cells
|
AR049635A1
(es)
|
2004-05-06 |
2006-08-23 |
Schering Corp |
(1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
|
JP2008505059A
(ja)
|
2004-05-06 |
2008-02-21 |
コンジュシェム バイオテクノロジーズ インコーポレイティド |
特異的ウイルス標的用化合物
|
WO2006016930A2
(en)
|
2004-05-14 |
2006-02-16 |
Intermune, Inc. |
Methods for treating hcv infection
|
US7514557B2
(en)
|
2004-05-25 |
2009-04-07 |
Boehringer Ingelheim International Gmbh |
Process for preparing acyclic HCV protease inhibitors
|
KR101370580B1
(ko)
|
2004-06-08 |
2014-03-06 |
버텍스 파마슈티칼스 인코포레이티드 |
약학 조성물
|
ATE497775T1
(de)
|
2004-07-14 |
2011-02-15 |
Novartis Pharma Gmbh |
Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
EP1627641A1
(en)
|
2004-08-04 |
2006-02-22 |
Victor Eluwa |
Pharmaceutical compositions comprising metal oxides and uses thereof
|
US7153848B2
(en)
|
2004-08-09 |
2006-12-26 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
US7348425B2
(en)
|
2004-08-09 |
2008-03-25 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
WO2006037052A2
(en)
|
2004-09-27 |
2006-04-06 |
Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health |
Modulating mxa expression
|
JP4892486B2
(ja)
|
2004-10-01 |
2012-03-07 |
デビオファーム ソシエテ アノニム |
C型肝炎感染の治療のための[d−meala]3−[etval]4−シクロスポリンの使用、及び当該[d−meala]3−[etval]4−シクロスポリンを含む医薬組成物
|
AU2005291918A1
(en)
|
2004-10-01 |
2006-04-13 |
Vertex Pharmaceuticals Incorporated |
HCV NS3-NS4A protease inhibition
|
US7723310B2
(en)
|
2004-10-18 |
2010-05-25 |
Three Rivers Pharmaceuticals, Llc |
Large dose ribavirin formulations
|
WO2006043153A2
(en)
|
2004-10-20 |
2006-04-27 |
Michel Xilinas |
Use of zinc and copper chelators for the treatment of viral diseases
|
US20060228333A1
(en)
|
2004-10-20 |
2006-10-12 |
Kye-Hyung Paik |
Methods for control of tumors and chronic infections by modulating immunologically informed carriers homing to tolerogenic organs or tissues
|
WO2006046030A2
(en)
|
2004-10-26 |
2006-05-04 |
Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Tetracyclic indole derivatives as antiviral agents
|
MY141025A
(en)
|
2004-10-29 |
2010-02-25 |
Vertex Pharma |
Dose forms
|
US7592315B2
(en)
|
2004-11-02 |
2009-09-22 |
Schering Corporation |
Peptide viral entry inhibitors
|
WO2006055711A1
(en)
|
2004-11-18 |
2006-05-26 |
Kent Hann |
Compositions containing aloe vera isolate and a prebiotic and their therapeutic application
|
JP2008523082A
(ja)
|
2004-12-09 |
2008-07-03 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
抗菌活性および抗癌活性を有するヌクレオチド
|
TW200633718A
(en)
|
2004-12-16 |
2006-10-01 |
Applied Research Systems |
Treatment of hepatitis c in the asian population
|
DE102004061746A1
(de)
|
2004-12-22 |
2006-07-06 |
Bayer Healthcare Ag |
Alkinyl-substituierte Thiophene
|
EP1674104A1
(en)
|
2004-12-24 |
2006-06-28 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV
|
EP1679065A1
(en)
|
2005-01-07 |
2006-07-12 |
OctoPlus Sciences B.V. |
Controlled release compositions for interferon based on PEGT/PBT block copolymers
|
BRPI0606647A2
(pt)
|
2005-01-17 |
2009-07-14 |
Jerini Ag |
antagonistas do receptor de c5a
|
EP2361630A1
(en)
|
2005-02-03 |
2011-08-31 |
Intarcia Therapeutics, Inc |
Implantable drug delivery device comprising particles and an osmotic pump
|
EP1853317A2
(en)
|
2005-02-09 |
2007-11-14 |
Migenix Inc. |
Compositions and methods for treating or preventing flaviviridae infections
|
US20060198787A1
(en)
|
2005-02-18 |
2006-09-07 |
Larry Blatt |
Biomarkers for predicting liver fibrosis treatment efficacy
|
US8232240B2
(en)
|
2005-02-23 |
2012-07-31 |
The Brigham And Women's Hospital, Inc. |
Inhibitors of enveloped virus infectivity
|
US20090156545A1
(en)
|
2005-04-01 |
2009-06-18 |
Hostetler Karl Y |
Substituted Phosphate Esters of Nucleoside Phosphonates
|
US20060229293A1
(en)
|
2005-04-06 |
2006-10-12 |
Addiction Research Institute, Inc. |
Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
|
EP1865967A4
(en)
|
2005-04-08 |
2011-02-09 |
Chimerix Inc |
COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND OTHER DISEASES
|
WO2006113431A2
(en)
|
2005-04-13 |
2006-10-26 |
University Of Massachusetts |
Dual functional oligonucleotides for use as anti-viral agents
|
US20060241144A1
(en)
|
2005-04-20 |
2006-10-26 |
Albert Cha |
Method for treating apathy syndrome
|
US7569600B2
(en)
|
2005-05-13 |
2009-08-04 |
Virochem Pharma Inc. |
Compounds and methods for the treatment of prevention of Flavivirus infections
|
WO2006127289A1
(en)
|
2005-05-20 |
2006-11-30 |
Valeant Research & Development |
Treatment of hcv with subtherapeutic doses of ribavirin
|
WO2006127482A1
(en)
|
2005-05-20 |
2006-11-30 |
Bioenvision, Inc. |
Methylene blue therapy of viral disease
|
JP2008545409A
(ja)
|
2005-05-26 |
2008-12-18 |
シェーリング コーポレイション |
インターフェロン−IgG融合体
|
EP1893198A2
(en)
|
2005-05-31 |
2008-03-05 |
Novartis AG |
Treatment of liver diseases in which iron plays a role in pathogenesis
|
US7793040B2
(en)
|
2005-06-01 |
2010-09-07 |
Microsoft Corporation |
Content addressable memory architecture
|
WO2006130552A2
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods of treating hepatitis c virus
|
US20070232527A1
(en)
|
2005-06-02 |
2007-10-04 |
Anima Ghosal |
Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
|
US20070237818A1
(en)
|
2005-06-02 |
2007-10-11 |
Malcolm Bruce A |
Controlled-release formulation of HCV protease inhibitor and methods using the same
|
US20060276407A1
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods of treating hepatitis C virus
|
WO2006130553A2
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Hcv protease inhibitors
|
US20060275366A1
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Controlled-release formulation
|
WO2006130686A2
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Hcv protease inhibitors in combination with food
|
US20060287248A1
(en)
|
2005-06-02 |
2006-12-21 |
Schering Corporation |
Asymmetric dosing methods
|
US20070021351A1
(en)
|
2005-06-02 |
2007-01-25 |
Schering Corporation |
Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
|
US20060276404A1
(en)
|
2005-06-02 |
2006-12-07 |
Anima Ghosal |
Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
|
US20070207949A1
(en)
|
2005-06-02 |
2007-09-06 |
Anima Ghosal |
Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
|
US20060281689A1
(en)
|
2005-06-02 |
2006-12-14 |
Schering Corporation |
Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
|
AU2006252553B2
(en)
|
2005-06-02 |
2012-03-29 |
Merck Sharp & Dohme Corp. |
Combination of HCV protease inhibitors with a surfactant
|
WO2006133092A1
(en)
|
2005-06-07 |
2006-12-14 |
Yale University |
Methods of treating cancer and other conditions or disease states using lfmau and ldt
|
RU2293572C1
(ru)
|
2005-07-18 |
2007-02-20 |
Гюнтер Хаазе |
Способ лечения хронического вирусного гепатита с генотип-2 с умеренной активностью
|
AR057456A1
(es)
|
2005-07-20 |
2007-12-05 |
Merck & Co Inc |
Inhibidores de la proteasa ns3 del vhc
|
PE20070211A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
US20070105781A1
(en)
|
2005-08-02 |
2007-05-10 |
Steve Lyons |
Inhibitors of serine proteases
|
AU2006280312A1
(en)
|
2005-08-12 |
2007-02-22 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
DE102005038768A1
(de)
|
2005-08-16 |
2007-02-22 |
Toximed Gmbh |
Pharmazeutischer Wirkstoff gegen Borreliose
|
ATE463480T1
(de)
|
2005-08-19 |
2010-04-15 |
Vertex Pharma |
Verfahren und zwischenprodukte
|
US8193328B2
(en)
|
2005-09-08 |
2012-06-05 |
Philadelphia Health & Education Corporation |
Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
|
US7531164B2
(en)
|
2005-10-21 |
2009-05-12 |
Duke University |
Preventing bacterial or viral infectivity and composition containing infection preventing additive
|
IE20050723A1
(en)
|
2005-10-28 |
2007-05-30 |
Patrick T Prendergast |
Anti-mineralocorticoid therapy of infection
|
WO2007056016A2
(en)
|
2005-11-02 |
2007-05-18 |
Kemia, Inc. |
Bisamide cytokine inhibitors
|
RU2306134C2
(ru)
|
2005-11-07 |
2007-09-20 |
Государственное образовательное учреждение высшего профессионального образования "Самарский Государственный медицинский университет" |
Способ базисного лечения хронического вирусного гепатита c
|
EP2392590A3
(en)
|
2005-11-11 |
2012-03-14 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
WO2007058384A1
(en)
|
2005-11-17 |
2007-05-24 |
Osaka University |
Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
|
RU2326115C2
(ru)
|
2005-11-21 |
2008-06-10 |
Ефаг АО |
Соли 1-алкиламино-1-дезоксиполиолов с 9-оксоакридин-10-уксусной кислотой, лекарственные препараты на их основе, применение, способы профилактики и лечения
|
AR057623A1
(es)
|
2005-11-28 |
2007-12-05 |
Omega Bio Pharma H K Ltd |
Materiales y metodos para el tratamiento de las infecciones virales
|
US8293726B2
(en)
|
2005-12-02 |
2012-10-23 |
Vianova Labs, Inc. |
Treatment of cancer and other diseases
|
MY150667A
(en)
|
2005-12-09 |
2014-02-28 |
Gilead Pharmasset Llc |
Antiviral nucleosides
|
WO2007075896A2
(en)
|
2005-12-22 |
2007-07-05 |
Kemia, Inc. |
Heterocyclic cytokine inhibitors
|
RU2306934C1
(ru)
|
2005-12-28 |
2007-09-27 |
ГОУ ВПО Омская Государственная Медицинская Академия |
Способ лечения больных хроническим вирусным гепатитом c
|
BRPI0706379A2
(pt)
|
2006-01-09 |
2011-03-22 |
Romark Lab Lc |
tratamento de hepatite viral
|
MD20060037A
(ro)
|
2006-01-24 |
2007-07-31 |
Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова |
Metodă de tratament al hepatitei virale acute C
|
TW200800265A
(en)
|
2006-02-09 |
2008-01-01 |
Schering Corp |
Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
|
EP1981523A2
(en)
|
2006-02-09 |
2008-10-22 |
Schering Corporation |
Novel hcv inhibitor combinations and methods
|
CN101489557B
(zh)
|
2006-02-27 |
2013-12-18 |
弗特克斯药品有限公司 |
包含vx-950的共晶体和包含所述共晶体的药物组合物
|
EP2194039A1
(en)
|
2006-03-16 |
2010-06-09 |
Vertex Pharmceuticals Incorporated |
Process for preparing optically enriched compounds
|
GEP20125378B
(en)
|
2006-03-20 |
2012-01-10 |
Vertex Pharma |
Pharmaceutical compositions
|
TW200812611A
(en)
|
2006-03-20 |
2008-03-16 |
Vertex Pharma |
Pharmaceutical compositions
|
JP2009530382A
(ja)
|
2006-03-23 |
2009-08-27 |
シェーリング コーポレイション |
Hcvプロテアーゼインヒビターとcyp3a4インヒビターとの組み合わせ、および関連する処置方法
|
US8895531B2
(en)
|
2006-03-23 |
2014-11-25 |
Rfs Pharma Llc |
2′-fluoronucleoside phosphonates as antiviral agents
|
EP2016100B1
(en)
|
2006-05-04 |
2014-07-09 |
The Rockefeller University |
Hcv coreceptor and methods of use thereof
|
US20100256217A1
(en)
|
2006-05-22 |
2010-10-07 |
The Trustees Of The University Of Pennsylvania |
Antiviral inhibition of casein kinase ii
|
DE102006026464A1
(de)
|
2006-06-01 |
2007-12-06 |
Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma |
Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
|
WO2007143164A1
(en)
|
2006-06-02 |
2007-12-13 |
San Diego State University Research Foundation |
Compositions and methods for ameliorating hyperlipidemia
|
CA2654130A1
(en)
|
2006-06-04 |
2007-12-13 |
Cellartis Ab |
Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
|
AU2007257959A1
(en)
|
2006-06-09 |
2007-12-21 |
Kemia, Inc. |
Therapy using cytokine inhibitors
|
WO2007149382A2
(en)
|
2006-06-19 |
2007-12-27 |
The Cleveland Clinic Foundation |
Therapeutic compositions and methods useful in treating hepatitis
|
RU2008152171A
(ru)
|
2006-07-05 |
2010-08-10 |
Интермьюн, Инк. (Us) |
Новые ингибиторы вирусной репликации гепатита с
|
US20080081791A1
(en)
|
2006-07-06 |
2008-04-03 |
Weida Huang |
Methods of using combinations of siRNAs for treating a disease or a disorder, and for enhancing siRNA efficacy in RNAi
|
EP2043658B1
(en)
|
2006-07-07 |
2012-04-25 |
Gilead Sciences, Inc. |
Antiviral phosphinate compounds
|
CA2657618C
(en)
|
2006-07-13 |
2016-10-11 |
Achillion Pharmaceuticals, Inc. |
4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
|
US8329159B2
(en)
|
2006-08-11 |
2012-12-11 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2008022006A2
(en)
|
2006-08-11 |
2008-02-21 |
Enanta Pharmaceuticals, Inc. |
Arylalkoxyl hepatitis c virus protease inhibitors
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
US20100158862A1
(en)
|
2006-08-11 |
2010-06-24 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
CA2666814A1
(en)
|
2006-08-21 |
2008-05-29 |
United Therapeutics Corporation |
Combination therapy for treatment of viral infections
|
WO2008073165A2
(en)
|
2006-08-25 |
2008-06-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for identifying anti-hcv agents
|
TW200815384A
(en)
|
2006-08-25 |
2008-04-01 |
Viropharma Inc |
Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein
|
AU2007286754A1
(en)
|
2006-08-25 |
2008-02-28 |
Viropharma Incorporated |
Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796, and methods related thereto
|
US9216197B2
(en)
|
2006-09-11 |
2015-12-22 |
Biomas Ltd. |
Topical formulations of tellurium-containing compounds
|
US20100254944A1
(en)
|
2006-09-14 |
2010-10-07 |
Mani Subramanian |
Albumin Fusion Proteins
|
US20080161324A1
(en)
|
2006-09-14 |
2008-07-03 |
Johansen Lisa M |
Compositions and methods for treatment of viral diseases
|
WO2008039179A1
(en)
|
2006-09-26 |
2008-04-03 |
Addiction Research Institute, Inc. |
Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c
|
SI2084174T1
(sl)
|
2006-10-10 |
2013-10-30 |
Gilead Pharmasset Llc |
Priprava nukleozidov ribofuranozil pririmidinov
|
US7777395B2
(en)
|
2006-10-12 |
2010-08-17 |
Eastman Kodak Company |
Continuous drop emitter with reduced stimulation crosstalk
|
RU2468029C2
(ru)
|
2006-10-27 |
2012-11-27 |
Иституто Ди Ричерке Ди Биолоджиа Молеколаре П.Анджелетти С.П.А. |
Ингибиторы hcv ns3 протеазы
|
EP2559692A1
(en)
|
2006-11-15 |
2013-02-20 |
Virochem Pharma Inc. |
Thiophene analogues for the treatment or prevention of Flavivirus infections
|
US20100093824A1
(en)
|
2006-11-29 |
2010-04-15 |
Judith Frydman |
Methods of treating viral infection
|
EP2099430A2
(en)
|
2006-12-07 |
2009-09-16 |
Schering Corporation |
Ph sensitive matrix formulation
|
RU2336096C1
(ru)
|
2006-12-14 |
2008-10-20 |
ООО Медицинский центр "Столица" |
Способ лечения гепатита с
|
RU2345787C2
(ru)
|
2006-12-25 |
2009-02-10 |
Государственное образовательное учреждение высшего профессионального образования "Самарский Государственный медицинский университет" |
Способ лечения хронического вирусного гепатита с
|
US20080261913A1
(en)
|
2006-12-28 |
2008-10-23 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of liver disorders
|
EP2111227A1
(en)
|
2007-01-08 |
2009-10-28 |
Phenomix Corporation |
Macrocyclic hepatitis c protease inhibitors
|
WO2008089034A2
(en)
|
2007-01-11 |
2008-07-24 |
Kemia, Inc. |
Cytokine inhibitors
|
US7645732B2
(en)
|
2007-01-24 |
2010-01-12 |
Board Of Regents, The University Of Texas System |
Treating hepatitis C virus infection
|
SI2118098T1
(sl)
|
2007-02-01 |
2015-01-30 |
Janssen R&D Ireland |
Polimorfne oblike makrocikličnega inhibitorja HCV
|
TWI426918B
(zh)
|
2007-02-12 |
2014-02-21 |
Merck Sharp & Dohme |
Il-23拮抗劑於治療感染之用途
|
WO2008103847A2
(en)
|
2007-02-21 |
2008-08-28 |
Allaccem, Incorporated |
Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
|
KR20090115970A
(ko)
|
2007-02-27 |
2009-11-10 |
버텍스 파마슈티칼스 인코포레이티드 |
공-결정 및 그를 포함하는 제약 조성물
|
WO2008106167A1
(en)
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
MD3477G2
(ro)
|
2007-03-21 |
2008-08-31 |
Николае БОДРУГ |
Metodă de tratament al hepatitei virale cronice C
|
US20100129437A1
(en)
|
2007-03-23 |
2010-05-27 |
Bbb Holding B.V. |
Targeted intracellular delivery of antiviral agents
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
WO2008124384A2
(en)
|
2007-04-03 |
2008-10-16 |
Aegerion Pharmaceuticals, Inc. |
Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c
|
CN101678122A
(zh)
|
2007-04-27 |
2010-03-24 |
奇默里克斯公司 |
在核苷给药的受体中降低肾中毒性的方法
|
US20080269205A1
(en)
|
2007-04-27 |
2008-10-30 |
Ondine International, Ltd. |
Methods to prevent vertical transmission of infectious diseases
|
KR20100024920A
(ko)
|
2007-05-03 |
2010-03-08 |
인터뮨, 인크. |
C형 간염 바이러스 복제의 신규 마크로사이클릭 저해제
|
ES2381410T3
(es)
|
2007-05-04 |
2012-05-28 |
Vertex Pharmceuticals Incorporated |
Terapia de combinación paa el tratamiento de infecciones por VHC
|
CL2008001381A1
(es)
|
2007-05-10 |
2008-11-03 |
Intermune Inc Y Array Biopharma Inc |
Compuestos derivados de tripeptidos que contienen heterociclos nitrogenados; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una infeccion de hepatitis c o vih.
|
MX2009012598A
(es)
|
2007-05-21 |
2009-12-07 |
Vertex Pharma |
Formas de dosis que comprenden vx-950 y su regimen de dosificacion.
|
RU2348412C1
(ru)
|
2007-06-01 |
2009-03-10 |
Лариса Леонидовна Попова |
Способ профилактики рецидива хронического вирусного гепатита с после достижения вирусологической ремиссии
|
WO2008154248A1
(en)
|
2007-06-06 |
2008-12-18 |
Inova Health System |
Prognostic chronic hepatitis c biomarkers
|
KR101596524B1
(ko)
|
2007-06-29 |
2016-02-22 |
길리애드 사이언시즈, 인코포레이티드 |
항바이러스 화합물
|
CN100532388C
(zh)
|
2007-07-16 |
2009-08-26 |
郑州大学 |
2’-氟-4’-取代-核苷类似物、其制备方法及应用
|
AU2008279087A1
(en)
|
2007-07-25 |
2009-01-29 |
Biolex Therapeutics, Inc. |
Controlled release interferon drug products and treatment of HCV infection using same
|
WO2009015389A2
(en)
|
2007-07-26 |
2009-01-29 |
Entra Pharmaceuticals Inc. |
Skin-patch pump comprising a changing-volume electrochemical actuator
|
ES2614269T3
(es)
|
2007-08-03 |
2017-05-30 |
Biotron Limited |
Procedimientos y composiciones antivíricas frente a la hepatitis C
|
US7728027B2
(en)
|
2007-08-08 |
2010-06-01 |
Bristol-Myers Squibb Company |
Process for synthesizing compounds useful for treating hepatitis C
|
US8629171B2
(en)
|
2007-08-08 |
2014-01-14 |
Bristol-Myers Squibb Company |
Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
|
US20110166092A1
(en)
|
2007-08-20 |
2011-07-07 |
Anadys Pharmaceuticals, Inc. |
Dosing methods for treating disease
|
US8492546B2
(en)
|
2007-08-30 |
2013-07-23 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical compositions comprising the same
|
WO2009033183A2
(en)
|
2007-09-08 |
2009-03-12 |
University Of Florida Research Foundation |
Compounds and methods for treatment of hcv and conditions associated with cd81 binding
|
US20090076100A1
(en)
|
2007-09-13 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched gsk625433
|
ATE519503T1
(de)
|
2007-09-14 |
2011-08-15 |
Schering Corp |
Verfahren zur behandlung von patienten mit hepatitis c
|
NZ600371A
(en)
|
2007-09-17 |
2014-07-25 |
Abbvie Bahamas Ltd |
Uracil or thymine derivative for treating hepatitis c
|
JP5734655B2
(ja)
|
2007-09-17 |
2015-06-17 |
アッヴィ・バハマズ・リミテッド |
抗感染症ピリミジンおよびその使用
|
EP2203168B1
(en)
|
2007-09-18 |
2014-07-16 |
Stanford University |
Compositions for treating a flaviviridae family viral infection
|
US20090082414A1
(en)
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched viramidine
|
US20090082366A1
(en)
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched telaprevir
|
BRPI0818178B1
(pt)
|
2007-10-03 |
2021-11-23 |
Sabell Corporation |
Composições herbais para tratar distúrbios hepáticos e método para obter extratos hidroalcoólicos de um órgão de planta selecionado
|
US20110270212A1
(en)
|
2007-10-05 |
2011-11-03 |
Medtronic, Inc. |
Pharmacokinetic control for optimized interferon delivery
|
JP2011503060A
(ja)
|
2007-11-05 |
2011-01-27 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Vx−950、peg−ifnおよびリババリンを含むhcv併用治療剤
|
CN102300570B
(zh)
|
2007-11-15 |
2015-01-14 |
马道斯有限责任公司 |
用于治疗肝炎的水飞蓟宾组分
|
TW201546079A
(zh)
|
2007-12-21 |
2015-12-16 |
Celgene Avilomics Res Inc |
Hcv蛋白酶抑制劑及其用途(一)
|
WO2009080542A1
(en)
|
2007-12-21 |
2009-07-02 |
F. Hoffmann-La Roche Ag |
Process for the preparation of a macrocycle
|
US8202996B2
(en)
|
2007-12-21 |
2012-06-19 |
Bristol-Myers Squibb Company |
Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
|
US20100298256A1
(en)
|
2007-12-27 |
2010-11-25 |
Steven Dong |
Antiviral compounds
|
WO2009109665A1
(en)
|
2008-03-07 |
2009-09-11 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microrna related diseases
|
JP5283106B2
(ja)
|
2008-03-14 |
2013-09-04 |
国立大学法人 熊本大学 |
C型肝炎ウイルス阻害剤
|
US20100009970A1
(en)
|
2008-03-19 |
2010-01-14 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions and methods for treatment of viral diseases
|
US20110045001A1
(en)
|
2008-03-28 |
2011-02-24 |
Biontex Laboratories Gmbh |
Transfection results of non-viral gene delivery systems by influencing of the innate immune system
|
MX2010011307A
(es)
|
2008-04-15 |
2010-11-09 |
Intermune Inc |
Nuevos inhibidores de la replicacion del virus de hepatitis c.
|
MX2010011580A
(es)
|
2008-04-23 |
2010-11-09 |
Vertex Pharma |
Tratamiento de infecciones por virus de hepatitis c con telaprevir (vx-950) en pacientes que no responden al tratamiento con interferon-alfa-2a-2b pegilado y ribavirina.
|
DE102008029669A1
(de)
|
2008-05-16 |
2009-11-19 |
Schlaak, Jörg Friedrich, Prof. Dr. med. |
Neue Therapeutika für die Hepatitis-Therapie
|
US20110218512A1
(en)
|
2008-06-03 |
2011-09-08 |
Aethlon Medical, Inc. |
Enhanced antiviral therapy methods and devices
|
CN103536906A
(zh)
|
2008-06-05 |
2014-01-29 |
津莫吉尼蒂克斯公司 |
利用聚乙二醇化的iii 型干扰素治疗丙型肝炎
|
RU2010153688A
(ru)
|
2008-06-10 |
2012-07-20 |
Янссен Фармацевтика Нв (Be) |
Режим дозирования телапревира
|
WO2009152589A1
(en)
|
2008-06-17 |
2009-12-23 |
Universidade Federal De Minas Gerais-Ufmg |
Use of paf receptor for treating infections caused by flaviviridae
|
BRPI0916235B8
(pt)
|
2008-07-22 |
2021-05-25 |
Merck Sharp & Dohme |
composto, composição farmacêutica, e, uso do composto ou da composição
|
US20100034839A1
(en)
|
2008-07-25 |
2010-02-11 |
Martha Karen Newell |
Methods for treating viral disorders
|
RU2373952C1
(ru)
|
2008-07-30 |
2009-11-27 |
Юрий Михайлович Амбалов |
Способ лечебного питания больных хроническим гепатитом с, получающих комплексную противовирусную терапию
|
CN102171186A
(zh)
|
2008-08-06 |
2011-08-31 |
赛生制药有限公司 |
采用免疫调节剂化合物治疗或预防丙型肝炎
|
KR101647520B1
(ko)
|
2008-08-07 |
2016-08-10 |
에프. 호프만-라 로슈 아게 |
거대환식 화합물의 제조 방법
|
EP2323631A1
(en)
|
2008-08-07 |
2011-05-25 |
Schering Corporation |
Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
|
WO2010021681A2
(en)
|
2008-08-18 |
2010-02-25 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions and methods for treatment of viral diseases
|
WO2010020676A1
(en)
|
2008-08-20 |
2010-02-25 |
Vib Vzw |
The use of topoisomerase type i inhibitors to treat viral infections
|
JP2012501345A
(ja)
|
2008-08-28 |
2012-01-19 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Hcv遺伝子型の分析
|
CN102137682B
(zh)
|
2008-08-29 |
2014-07-02 |
国立大学法人大阪大学 |
抗丙型肝炎病毒组合物
|
EP2323622A1
(en)
|
2008-09-03 |
2011-05-25 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical formulations comprising the same
|
UY32099A
(es)
*
|
2008-09-11 |
2010-04-30 |
Enanta Pharm Inc |
Inhibidores macrocíclicos de serina proteasas de hepatitis c
|
DK2331538T3
(da)
|
2008-09-16 |
2014-06-02 |
Boehringer Ingelheim Int |
Krystallinske former af en 2-thiazolyl-4-quinolinyl-oxy-derivat, en potent HCV-inhibitor
|
EP2337583A1
(en)
|
2008-09-17 |
2011-06-29 |
Boehringer Ingelheim International GmbH |
Combination of hcv ns3 protease inhibitor with interferon and ribavirin
|
WO2010031832A2
(en)
|
2008-09-18 |
2010-03-25 |
Ortho-Mcneil-Janssen Pharmaceuticals, Inc |
Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
|
CA2738477A1
(en)
|
2008-09-24 |
2010-04-01 |
Robert S. Kauffman |
Therapeutic regimen comprising peg-interferon, ribavirin and vx-950 for the treatment of hepatitis
|
CN102227237A
(zh)
|
2008-09-26 |
2011-10-26 |
国家健康与医学研究院 |
作为针对hcv感染的抗病毒治疗的靶标的宿主细胞激酶
|
CA2738985A1
(en)
|
2008-09-30 |
2010-04-08 |
Mochida Pharmaceutical Co., Ltd. |
Therapeutic agent for hepatitis c
|
EP2341924A4
(en)
|
2008-10-02 |
2013-01-23 |
David Gladstone Inst |
METHOD FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS
|
CN102257140A
(zh)
|
2008-10-08 |
2011-11-23 |
夏洛特-梅克伦堡医院管理局D/B/A卡罗莱纳医学中心 |
用微rna-196的过表达治疗丙型肝炎病毒感染
|
JP2012505897A
(ja)
|
2008-10-15 |
2012-03-08 |
インターミューン・インコーポレーテッド |
治療用抗ウイルス性ペプチド
|
WO2010049438A2
(en)
|
2008-10-30 |
2010-05-06 |
Innate Pharma |
Improved methods of using phosphoantigens for the treatment of diseases
|
WO2010053942A1
(en)
|
2008-11-05 |
2010-05-14 |
Vertex Pharmaceuticals Incorporated |
Methods for treating hepatitis c virus infection
|
NZ592383A
(en)
|
2008-11-21 |
2012-11-30 |
Boehringer Ingelheim Int |
Pharmaceutical composition of a potent hcv inhibitor for oral administration
|
CN102245599B
(zh)
|
2008-12-10 |
2014-05-14 |
艾其林医药公司 |
作为病毒复制抑制剂的新的4-氨基-4-氧代丁酰基肽
|
EP2356236B1
(en)
|
2008-12-11 |
2015-07-29 |
Xiangxue Group (Hong Kong) Company Limited |
siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING VIRAL INFECTION
|
JP2012512636A
(ja)
|
2008-12-18 |
2012-06-07 |
エフ.ホフマン−ラ ロシュ アーゲー |
Hcv処置応答についてのバイオマーカー
|
EP2376514A2
(en)
|
2008-12-23 |
2011-10-19 |
Pharmasset, Inc. |
Nucleoside analogs
|
EP2808402A3
(en)
|
2008-12-29 |
2015-03-25 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
Methods of predicting responsiveness to interferon treatment
|
US8840934B2
(en)
|
2009-01-02 |
2014-09-23 |
Rainbow Pharmaceutical Sa |
Uses of ammonium chloride
|
CN102348712A
(zh)
|
2009-01-09 |
2012-02-08 |
卡迪夫大学学院顾问有限公司 |
用于治疗病毒感染的鸟苷核苷类化合物的磷酰胺酯衍生物
|
RU2398582C1
(ru)
|
2009-01-19 |
2010-09-10 |
Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.М. Мечникова Федерального агентства по здравоохранению и социальному развитию" |
Способ лечения хронического вирусного гепатита с 1-генотипа с умеренной активностью и репликативностью
|
JP2012517478A
(ja)
|
2009-02-12 |
2012-08-02 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、hcv組合せ治療剤
|
AR075584A1
(es)
|
2009-02-27 |
2011-04-20 |
Intermune Inc |
COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
|
US8101643B2
(en)
|
2009-02-27 |
2012-01-24 |
Enanta Pharmaceuticals, Inc. |
Benzimidazole derivatives
|
CA2753001A1
(en)
|
2009-03-05 |
2010-09-10 |
Ascendis Pharma As |
Interferon alpha carrier prodrugs
|
WO2010101649A2
(en)
|
2009-03-05 |
2010-09-10 |
Pablo Gastaminza |
Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection
|
ES2599979T3
(es)
|
2009-04-24 |
2017-02-06 |
Roche Innovation Center Copenhagen A/S |
Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
|
SI2421527T1
(sl)
|
2009-04-25 |
2018-09-28 |
F. Hoffmann-La Roche Ag |
Metode za izboljšanje farmakokinetike
|
HUE036906T2
(hu)
|
2009-05-13 |
2018-08-28 |
|
Antivirális vegyületek
|
TWI583692B
(zh)
|
2009-05-20 |
2017-05-21 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
KR20140014375A
(ko)
|
2009-05-21 |
2014-02-06 |
머크 샤프 앤드 돔 코포레이션 |
인터페론-알파 반응과 연관된 유전자 마커
|
UY32699A
(es)
*
|
2009-06-11 |
2010-12-31 |
Abbott Lab |
Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv"), procesos, composiciones, y métodos relacionados
|
UY32715A
(es)
|
2009-06-23 |
2011-01-31 |
Gilead Sciences Inc |
Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
|
AR077139A1
(es)
|
2009-06-23 |
2011-08-03 |
Gilead Sciences Inc |
Composiciones farmaceuticas utiles para tratar el vch
|
TW201113279A
(en)
|
2009-06-23 |
2011-04-16 |
Gilead Sciences Inc |
Pharmaceutical compositions useful for treating HCV
|
CN108042535A
(zh)
|
2009-06-26 |
2018-05-18 |
罗马克实验室有限公司 |
用于治疗流感的化合物和方法
|
NZ596928A
(en)
|
2009-07-07 |
2013-05-31 |
Boehringer Ingelheim Int |
A liquid- or semi-solid pharmaceutical composition of a hepatitis C viral protease inhibitor
|
RU2400229C1
(ru)
|
2009-07-13 |
2010-09-27 |
Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" |
СПОСОБ ЛЕЧЕНИЯ БОЛЬНЫХ ХРОНИЧЕСКИМ ВИРУСНЫМ ГЕПАТИТОМ С, ГЕНОТИПОМ 3а
|
US20110020272A1
(en)
|
2009-07-24 |
2011-01-27 |
Ulrich Schubert |
Combination therapy for treating hepatitis viral infection
|
US20110027229A1
(en)
|
2009-07-31 |
2011-02-03 |
Medtronic, Inc. |
Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
|
EP2459210A1
(en)
|
2009-07-31 |
2012-06-06 |
Centre Hospitalier Universitaire Vaudois (CHUV) |
Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients
|
CA2770338A1
(en)
|
2009-08-27 |
2011-03-03 |
Merck Sharp & Dohme Corp. |
Processes for preparing protease inhibitors of hepatitis c virus
|
WO2011038224A1
(en)
|
2009-09-24 |
2011-03-31 |
Trustees Of Boston University |
Methods for treating viral disorders
|
WO2011041551A1
(en)
|
2009-10-01 |
2011-04-07 |
Intermune, Inc. |
Therapeutic antiviral peptides
|
US8415374B2
(en)
|
2009-10-12 |
2013-04-09 |
Bristol-Myers Squibb Company |
Combinations of hepatitis C virus inhibitors
|
US9174988B2
(en)
|
2009-10-27 |
2015-11-03 |
Trustees Of Boston University |
Small molecule inhibitors of hepatitis C virus
|
US8729058B2
(en)
|
2009-10-27 |
2014-05-20 |
Michael Zasloff |
Methods and compositions for treating and preventing viral infections
|
MX2012004971A
(es)
|
2009-10-30 |
2012-06-12 |
Boehringer Ingelheim Int |
Regimenes de dosificacion para terapia combinada del vhc, que comprende b1201335, interferon alfa y ribavirina.
|
EP2499263A2
(en)
|
2009-11-09 |
2012-09-19 |
Merck Sharp & Dohme Corp. |
Markers associated with ribavirin-induced anemia
|
US20110117055A1
(en)
|
2009-11-19 |
2011-05-19 |
Macdonald James E |
Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
|
WO2011066260A2
(en)
|
2009-11-25 |
2011-06-03 |
Michael Zasloff |
Formulations comprising aminosterols
|
KR20120116404A
(ko)
|
2009-12-18 |
2012-10-22 |
베링거 인겔하임 인터내셔날 게엠베하 |
Hcv 병용 요법
|
WO2011079016A1
(en)
|
2009-12-22 |
2011-06-30 |
Gilead Sciences, Inc. |
Methods of treating hbv and hcv infection
|
SG181904A1
(en)
|
2009-12-23 |
2012-07-30 |
Novartis Ag |
Lipids, lipid compositions, and methods of using them
|
RU2424794C1
(ru)
|
2009-12-30 |
2011-07-27 |
Государственное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО УГМА Росздрава) |
Способ лечения врожденного гепатита с у детей первого года жизни
|
KR20120139699A
(ko)
|
2010-01-29 |
2012-12-27 |
버텍스 파마슈티칼스 인코포레이티드 |
C형 간염 바이러스 감염의 치료 요법
|
CN104771364B
(zh)
|
2010-03-10 |
2018-05-25 |
艾伯维巴哈马有限公司 |
固体组合物
|
US8530497B2
(en)
|
2010-03-11 |
2013-09-10 |
Boehringer Ingelheim International Gmbh |
Crystalline salts of a potent HCV inhibitor
|
US8859756B2
(en)
|
2010-03-31 |
2014-10-14 |
Gilead Pharmasset Llc |
Stereoselective synthesis of phosphorus containing actives
|
AR084393A1
(es)
*
|
2010-06-10 |
2013-05-15 |
Gilead Sciences Inc |
Metodos para tratar el virus de la hepatitis c, composicion, uso, combinacion, kit y uno o mas compuestos anti vhc
|
NZ605440A
(en)
*
|
2010-06-10 |
2014-05-30 |
Abbvie Bahamas Ltd |
Solid compositions comprising an hcv inhibitor
|
US8592372B2
(en)
|
2010-06-29 |
2013-11-26 |
King Saud University Liver Disease |
Pharmaceutical composition and method of use to improve organ function
|
RU2429877C1
(ru)
|
2010-06-30 |
2011-09-27 |
Общество с ограниченной ответственностью "ИНГИЛС" |
Способ лечения хронического вирусного гепатита с
|
TW201208704A
(en)
|
2010-07-14 |
2012-03-01 |
Vertex Pharma |
Palatable pharmaceutical composition
|
JP2013535469A
(ja)
|
2010-07-30 |
2013-09-12 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Cyp3a薬物代謝の阻害
|
US20120196272A1
(en)
|
2010-08-05 |
2012-08-02 |
Roche Molecular Systems, Inc. |
Prediction of HCV Viral Kinetics in Interferon-Free Treatment
|
US20120196794A1
(en)
*
|
2010-08-06 |
2012-08-02 |
Bristol-Myers Squibb Company |
Combinations of Hepatitis C Virus Inhibitors
|
MX2013003153A
(es)
|
2010-09-22 |
2013-05-01 |
Alios Biopharma Inc |
Analogos de nucleotidos sustituidos.
|
CA2811752A1
(en)
|
2010-09-29 |
2012-04-19 |
Merck Sharp & Dohme Corp. |
Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
|
MX2013003060A
(es)
|
2010-09-30 |
2013-05-30 |
Boehringer Ingelheim Int |
Terapia de combinacion para tratar infeccion por hcv.
|
US20120107278A1
(en)
|
2010-10-29 |
2012-05-03 |
Pharmasset, Inc. |
Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype
|
WO2012087596A1
(en)
|
2010-12-20 |
2012-06-28 |
Gilead Sciences, Inc. |
Combinations for treating hcv
|
WO2012139028A2
(en)
|
2011-04-06 |
2012-10-11 |
The Trustees Of Princeton University |
Anti-viral combination therapy
|
JP2014522814A
(ja)
|
2011-06-23 |
2014-09-08 |
ステラ・アンパルトセルスカブ |
Hcv併用療法
|
WO2013000855A1
(en)
|
2011-06-30 |
2013-01-03 |
Santaris Pharma A/S |
Hcv combination therapy
|
EP2726611A1
(en)
|
2011-06-30 |
2014-05-07 |
Stella ApS |
Hcv combination therapy
|
WO2013024158A1
(en)
|
2011-08-17 |
2013-02-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
|
WO2013025975A1
(en)
|
2011-08-17 |
2013-02-21 |
Glaxosmithkline Llc |
Combination treatments for hepatitis c
|
WO2013024155A1
(en)
|
2011-08-17 |
2013-02-21 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection
|
BR112014004182A2
(pt)
|
2011-08-24 |
2017-03-14 |
Glaxosmithkline Llc |
métodos para tratar a hepatite c, para tratamento contra o vírus da hepatite c, e para prevenir ou tratar a hepatite c, e, composição
|
KR101991298B1
(ko)
*
|
2011-09-16 |
2019-06-21 |
길리애드 파마셋 엘엘씨 |
Hcv 치료 방법
|
JP2014530195A
(ja)
|
2011-09-16 |
2014-11-17 |
アッヴィ・インコーポレイテッド |
Hcvを治療するための方法
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
US8853176B2
(en)
|
2011-10-21 |
2014-10-07 |
Abbvie Inc. |
Methods for treating HCV
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
CN104023726A
(zh)
|
2011-10-21 |
2014-09-03 |
艾伯维公司 |
用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333)
|
RU2014122154A
(ru)
|
2011-10-31 |
2015-12-10 |
Мерк Шарп И Доум Корп. |
Композиции, пригодные для лечения вирусных заболеваний
|
US20130137084A1
(en)
|
2011-11-28 |
2013-05-30 |
Roche Molecular Systems, Inc. |
Single Nucleotide Polymorphism on Chromosome 15 That Predicts HCV Treatment Responses
|
US8980865B2
(en)
|
2011-12-22 |
2015-03-17 |
Alios Biopharma, Inc. |
Substituted nucleotide analogs
|